Mecasermin rinfabate
Increlex, Iplex (mecasermin rinfabate) is a protein pharmaceutical. Mecasermin rinfabate was first approved as Iplex on 2005-12-12. It has been approved in Europe to treat laron syndrome.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| increlex | Biologic Licensing Application | 2024-03-20 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
mecasermin rinfabate, Iplex, Insmed Incorporated | |||
| 2112-12-12 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
250 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acromegaly | D000172 | — | — | — | 3 | 8 | 6 | 11 | 28 |
| Laron syndrome | D046150 | Orphanet_633 | E34.321 | 2 | 7 | 4 | 4 | 4 | 18 |
| Dwarfism | D004392 | HP_0003510 | E34.31 | 1 | 4 | 2 | 2 | 4 | 11 |
| Pituitary dwarfism | D004393 | EFO_1001109 | E23.0 | 1 | 4 | — | 3 | 4 | 11 |
| Failure to thrive | D005183 | — | — | 1 | 1 | 2 | 1 | 2 | 6 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | — | — | 1 | 4 | 5 |
| Heart failure | D006333 | HP_0001635 | I50 | 1 | 2 | — | 1 | 2 | 5 |
| Wounds and injuries | D014947 | — | T14.8 | — | 1 | — | 1 | 3 | 5 |
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | — | 2 | 1 | 1 | 1 | 5 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.9 | — | — | — | 2 | 2 | 4 |
Show 24 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 2 | 1 | — | 8 | 10 |
| Syndrome | D013577 | — | — | 1 | 6 | 3 | — | 2 | 10 |
| Anorexia | D000855 | HP_0002039 | R63.0 | 2 | 4 | 3 | — | 2 | 8 |
| Anorexia nervosa | D000856 | EFO_0004215 | F50.0 | 2 | 4 | 3 | — | 2 | 8 |
| Growth disorders | D006130 | — | — | — | 2 | 3 | — | 2 | 6 |
| Pituitary diseases | D010900 | — | E23.7 | — | 1 | 1 | — | 3 | 5 |
| Fibrosis | D005355 | — | — | 2 | 2 | 2 | — | 1 | 5 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | 3 | 1 | — | 1 | 5 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | 2 | 1 | — | 2 | 5 |
| Myofascial pain syndromes | D009209 | EFO_1001054 | — | — | 2 | 1 | — | 2 | 5 |
Show 35 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 5 | 3 | — | — | 3 | 10 |
| Osteoporosis | D010024 | HP_0000939 | M81.0 | 1 | 1 | — | — | 3 | 4 |
| Sarcoma | D012509 | — | — | — | 2 | — | — | 2 | 4 |
| Insulin resistance | D007333 | HP_0000855 | — | 2 | 2 | — | — | 1 | 4 |
| Rectal neoplasms | D012004 | — | — | — | 3 | — | — | — | 3 |
| Healthy volunteers/patients | — | — | — | — | 1 | — | — | 2 | 3 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 2 | — | — | 1 | 3 |
| Chromosome disorders | D025063 | EFO_0003831 | Q99.9 | — | 3 | — | — | — | 3 |
| Chromosome deletion | D002872 | — | — | — | 3 | — | — | — | 3 |
| Retinopathy of prematurity | D012178 | EFO_1001158 | H35.1 | — | 3 | — | — | — | 3 |
Show 72 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | 2 | — | — | — | 1 | 3 |
| Colorectal neoplasms | D015179 | — | — | 1 | — | — | — | 1 | 2 |
| Aging | D000375 | GO_0007568 | R41.81 | 1 | — | — | — | 1 | 2 |
| Lipodystrophy | D008060 | HP_0009125 | E88.1 | 1 | — | — | — | 1 | 2 |
| Glioma | D005910 | EFO_0000520 | — | 1 | — | — | — | — | 1 |
| Brain stem neoplasms | D020295 | EFO_1001767 | — | 1 | — | — | — | — | 1 |
| Pinealoma | D010871 | — | — | 1 | — | — | — | — | 1 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | — | — | — | — | 1 |
| Joint instability | D007593 | — | — | 1 | — | — | — | — | 1 |
| Tendinopathy | D052256 | EFO_1001434 | M77.9 | 1 | — | — | — | — | 1 |
Show 3 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Metabolic bone diseases | D001851 | HP_0000938 | — | — | — | — | — | 3 | 3 |
| Igg deficiency | D017099 | HP_0004315 | D80.3 | — | — | — | — | 3 | 3 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | — | — | 2 | 2 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | — | — | — | 2 | 2 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | — | 2 | 2 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 2 | 2 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | — | — | — | 1 | 1 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | — | 1 | 1 |
| Anemia | D000740 | HP_0001903 | D64.9 | — | — | — | — | 1 | 1 |
| Vascular dementia | D015140 | — | F01 | — | — | — | — | 1 | 1 |
Show 91 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Mecasermin rinfabate |
| INN | mecasermin rinfabate |
| Description | Mecasermin rinfabate (INN, USAN) (brand name Iplex), also known as rhIGF-1/rhIGFBP-3, is a drug consisting of recombinant human insulin-like growth factor 1 (IGF-1) and recombinant human insulin-like growth factor binding protein-3 (IGFBP-3) which is used for the treatment of amyotrophic lateral sclerosis (Lou Gehrig's disease).
|
| Classification | Protein |
| Drug class | growth factors: insulin-like growth factors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201717 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | NZ8M50KKRG (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,031 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,669 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use